<DOC>
	<DOCNO>NCT00739388</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , azacitidine , work different way stop growth cancer cell , either kill cell stop dividing . PURPOSE : This phase II trial study well azacitidine work treat patient acute myeloid leukemia unsuitable treatment intensive chemotherapy .</brief_summary>
	<brief_title>Azacitidine Treating Patients With Newly Diagnosed Previously Untreated Secondary Acute Myeloid Leukemia Who Are Unsuitable For Intensive Chemotherapy</brief_title>
	<detailed_description>OBJECTIVES : Primary - To evaluate efficacy azacitidine patient newly diagnose untreated acute myeloid leukemia unsuitable induction type chemotherapy age relevant comorbidities . Secondary - To evaluate survival adverse event . OUTLINE : This multicenter study . Patients receive azacitidine subcutaneously day 1-5 . Treatment repeat every 28 day 6 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 3 month 1 year every 6 month 1 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis 1 following : De novo acute myeloid leukemia ( AML ) AML secondary prior hematological disease cytotoxic treatment Newly diagnose untreated disease At least 20 % blast blood bone marrow extramedullary disease Must consider unsuitable intensive chemotherapy due ≥ 1 following : High age frail biologic age Relevant comorbidities Unwilling undergo intensive chemotherapy No chronic myelogenous leukemia acute promyelocytic leukemia PATIENT CHARACTERISTICS : WHO performance status 03 Bilirubin ≤ 3 time upper limit normal ( ULN ) Alkaline phosphatase ≤ 2.5 time ULN AST ≤ 2.5 time ULN Serum creatinine ≤ 2.5 time ULN Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 12 month completion study treatment Patient compliance geographic proximity allow proper stag followup No NYHA class IIIIV heart failure relevant cardiac arrhythmia No active hematological/oncological disease AML No psychiatric disorder preclude understanding information trial related topic give informed consent No serious underlie medical condition judgment investigator , could impair ability patient participate trial , include limited , follow : Active autoimmune disease Uncontrolled diabetes Active uncontrolled infection HIV infection Active chronic hepatitis B C infection No known allergy hypersensitivity azacitidine mannitol PRIOR CONCURRENT THERAPY : No prior treatment AML No prior azacitidine decitabine No concurrent experimental investigational drug anticancer therapy More 30 day since participation another clinical trial No concurrent growth factor use afebrile asymptomatic patient except treat neutropenic infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>untreated adult acute myeloid leukemia</keyword>
	<keyword>adult acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>adult acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>adult acute myelomonocytic leukemia ( M4 )</keyword>
	<keyword>adult acute monoblastic leukemia ( M5a )</keyword>
	<keyword>adult acute monocytic leukemia ( M5b )</keyword>
	<keyword>adult erythroleukemia ( M6a )</keyword>
	<keyword>adult pure erythroid leukemia ( M6b )</keyword>
	<keyword>adult acute megakaryoblastic leukemia ( M7 )</keyword>
</DOC>